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ABSTRACT
Aim: To compare the conjunctival and corneal reactions
of commercially available solution of latanoprost (Xalatan)
and preservative-free (PF) tafluprost in rabbits.
Methods: The rabbits received 50 ml of phosphate-
buffered saline (PBS), PF-tafluprost 0.0015%, latanoprost
0.005% or benzalkonium chloride (BAK) 0.02%; all
solutions were applied at 5 min intervals for a total of 15
times. The ocular surface toxicity was investigated using
slit-lamp biomicroscopy examination, flow cytometry
(FCM) and on imprints for CD45 and tumour necrosis
factor-receptor 1 (TNFR1) conjunctival impression cytol-
ogy (CIC) and corneal in vivo confocal microscopy (IVCM).
Standard immunohistology also assessed inflammatory/
apoptotic cells.
Results: Clinical observation and IVCM images showed
the highest ocular surface toxicity with latanoprost and
BAK, while PF-tafluprost and PBS eyes presented almost
normal corneoconjunctival aspects. FCM showed a higher
expression of CD45+ and TNFR1+ in latanoprost- or BAK-
instilled groups, compared with PF-tafluprost and PBS
groups. Latanoprost induced fewer positive cells for
inflammatory marker expressions in CIC specimens
compared with BAK-alone, both of which were higher
than with PF-tafluprost or PBS. Immunohistology showed
the same tendency of toxic ranking.
Conclusion: The authors confirm that rabbit corneocon-
junctival surfaces presented a better tolerance when
treated with PF-tafluprost compared with commercially
available latanoprost or BAK solution.
Prostaglandins (PGs) occupy centre stage among
glaucoma medications.
1 Currently, four different PG
analogues—isopropyl unoprostone, latanoprost, tra-
voprost and bimatoprost—are used for the treat-
ment of glaucoma. These four PGs are superior to
beta-adrenoceptor antagonists in terms of lowering
intraocular pressure (IOP), and they have no severe
side effects during long-term clinical use.
23
Benzalkoniumchloride(BAK)isthemostcommonly
used preservative in eye-drops. However, during in
vitro and ex vivo studies, eye-drops containing
different doses of BAK had an effect on the ocular
surface,possiblyduetothepresenceofBAK.
4–6Incell
culture, it was seen that BAK induced epithelial cell
death,
7 pro-inflammatory or pro-apoptotic media-
tors,
8 and oxidative stress, including mitochondrial
activity and glutathione injury.
9 On the ocular
surface of patients with glaucoma, BAK induced
complex inflammatory mechanisms, causing both
allergy and toxicity.
4
New PG formulations without BAK and without
preservatives are currently in development. One
such example is travoprost Z, in which BAK has
been replaced with the Sofzia preservative system.
This is an Alcon patent containing borate, sorbitol,
propylene glycol and zinc chloride as a microbial-
contamination-prevention system. Exempt of pre-
servative, it might contribute to a better behaviour
on the ocular surface.
10 11 In vitro studies using
Chang conjunctiva-derived cells have shown that
travoprost Z presents no pro-apoptotic or oxidative
stress effects.
11 Tafluprost is a newly synthesised
PG F2a-agonist currently in development.
12 13
Tafluprost is highly selective for FP receptors and
is a more potent agonist than latanoprost.
12–14 In
vitro studies have shown a reduction in toxicity
with preservative-free (PF) tafluprost in human
conjunctival epithelial cell lines.
15
We developed in vivo tools for the analysis of
experimental toxic models consisting of in vivo
confocal microscopy (IVCM) and flow cytometry
(FCM) evaluation of conjunctival impression
cytology (CIC).
16–20 The combination of these two
in vivo and ex vivo tools is significant as they are
reliable for the observation, at a cellular level, of
toxic and/or immunoallergic reactions on the
ocular surface, and can analyse inflammation and
apoptosis in the conjunctival epithelium without
the need for sacrificing the test animal. In this
study, we have combined these two techniques to
evaluate the toxicological profiles of PF-tafluprost,
commercially available latanoprost and 0.02%
BAK, which is the concentration of BAK used in
the commercial solution of latanoprost.
MATERIALS AND METHODS
Animals and eye-drop treatments
Adult male New Zealand albino rabbits weighing
2.5–3.0 kg were treated according to the guidelines
issued by the Association for Research in Vision
and Ophthalmology. Before all experiments, rab-
bits were all anaesthetised.
In total, 24 rabbits were divided into four
groups. Each group was composed of six rabbits:
five rabbits were used for clinical and IVCM
observations at 4 h (H4) and day (D) 1 to D7 after
the administration of the treatment, and the
remaining rabbit was sacrificed for immunohisto-
logical procedures at D1, a time point chosen for
the maximal inflammatory infiltration time as a
previous study
18 and IVCM observation. Eye-drops
were instilled according to the model described by
Laboratory science
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21 Each of the four groups of rabbits was given a
different treatment: 50 ml of phosphate-buffered saline (PBS); PF-
tafluprost 0.0015% ophthalmic solution (Santen Oy, Tampere,
Finland), commercially available latanoprost 0.005% ophthalmic
solution (Xalatan, Pfizer, New York) or PBS containing 0.02%
BAK. All solutions were applied using a micropipette to both eyes
of the rabbits at 5 min intervals for a total of 15 times.
Clinical findings and Draize test
The time was noted when obvious redness occurred on the
ocular surface, calculated from the first instillation. Eyes were
examined by slit-lamp biomicroscopy and were scored according
to a modified Draize test.
16–18
IVCM evaluation
The Heidelberg Retina Tomograph II/Rostock Cornea Module
(Heidelberg Engineering GmbH, Heidelberg, Germany) laser-
scanning IVCM was used to examine the rabbits.
16–18 22 IVCM
scores were used to evaluate ocular surface toxicity profiles in
four histological zones (table 1).
18
Cresyl violet staining and FCM analysis in CIC
CIC specimens were collected as in previous studies for further
cresyl violet cytology (1%, no. 5235, Merck, Fontenay sous bois,
France) or FCM (FC500, Beckman Coulter, Miami, FL) proce-
dures.
16 18–20 Membranes of 0.2 mm porosity were applied to the
superior bulbar conjunctiva: two in nitrocellulose for cytology
(Millipore, Bedford, MA) and two in polyether sulfone (Supor
2200 Pall Life Sciences, Ann Arbor, MI) for FCM procedures. We
evaluated the CIC according to a modified Nelson classification.
23
Direct and indirect immunofluorescence procedures were used by
FCM to study the expressions of tumour necrosis factor-receptor
1 (TNFR1; 1:40 dilution, R&D Systems, Minneapolis, MN) and
rabbit CD45 (1:50, CBL1412, Cymbus Biotechnology, Chandlers
Ford, UK). CD45 (leucocyte common marker) and TNFR1 have
been used to assess inflammatory and/or toxicological phenom-
enon in animal models.
16 18
Cryosections and immunohistology
Cryosections of enucleated eyes at D1 were prepared and
incubated with antibodies to CD45/TUNEL assay (Roche
Diagnostics, Meylan, France) to detect inflammatory/apoptotic
cell infiltration, and counted using a fluorescent microscope
(Olympus BX-UCB, Olympus, Melville, NY) equipped with a
DP70 Olympus digital camera.
Statistical analysis
Results were expressed as mean (SE). For Draize and IVCM
scores, comparisons among the groups were performed by non-
parametric comparisons (Mann–Whitney U test). Comparisons
among the groups for CIC expressions and immunopositive cells
counts were performed by factorial analysis of variance
(ANOVA) followed by the Fisher method for pairwise
comparisons (Statview V; SAS Institute, Cary, NC).
RESULTS
Clinical findings
PBS and PF-tafluprost groups (fig 1A,B) presented the same
aspects as found in normal rabbit eyes without any obvious
abnormality. However, the latanoprost (fig 1C) and BAK
(fig 1D) groups induced diffuse hyperaemia, chemosis and
secretions on the conjunctiva. Latanoprost and BAK induced
conjunctival redness very quickly after the first instillation (16.3
(SE 0.82) min and 13.5 (1.07) min, respectively). Tafluprost
presented a slight and late redness (48.2 (3.83) min; p,0.0001
compared with BAK and latanoprost groups).
The PF-tafluprost group showed no statistical difference in
ocular Draize scores compared with the PBS group (fig 1E). At
Table 1 In vivo confocal microscopy scoring for the evaluation of ocular toxicity in the cornea, limbus and conjunctiva (maximum score: 40)
Eye zone Toxicity seen
In vivo confocal
microscopy score
Superficial epithelium (max points 10) Desquamation: 2
Partial
Total important 4
Shape/size: anisocytosis, microcytosis, macrocytosis, irregular shape, oedematous cells, swollen cells,
loss of cell borders
2
Reflectivity: abnormal reflectivity patterns, hyper-reflective cells, nuclei not visible in hyper-reflective cells 2
Inflammation: presence of inflammatory infiltration 2




















Limbus and conjunctiva (max 10 points) Presence of capillary bud from limbal vessels (tendency toward neovascularisation) 2
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(p,0.005forboth)andPF-tafluprost(p,0.01forboth)groups.At
D1, the latanoprost group returned to a normal aspect without
any statistical differences compared with the PBS or PF-tafluprost
groups. However, ocular changes were still observed at D1 for
BAK with higher scores than for PBS (p,0.005), PF-tafluprost
(p,0.01) and even latanoprost (p,0.05).
IVCM images and IVCM score
Superficial epithelium
At D1 after instillation, PBS- and PF-tafluprost-instilled rabbits
presented almost normal aspects of the corneal epithelium, with
a regular polygonal mosaic appearance, brightly reflective nuclei
and no obvious desquamation or swelling (fig 2.1A,B).
Latanoprost and BAK solutions induced various pathological
aspects of the corneal epithelium including partial desquama-
tion of epithelial cells, irregular cell shapes, anisocytosis and loss
of cell borders, abnormal reflectivity patterns, swollen cells and
inflammatory infiltration (fig 2.1C,D).
Basal epithelium
PBS (fig 2.2A) and PF-tafluprost (fig 2.2B) did not induce any
inflammation. Latanoprost (fig 2.2C) and BAK (fig 2.2D)
induced important inflammatory cell infiltration but at
significantly different levels (H4: 52 (5.32) cells/mm
2 for
latanoprost vs 106 (9.17) cells/mm
2 for BAK, p,0.0001; and
D1: 53 (7.95) cells/mm
2 for latanoprost vs 130 (13.38) cells/mm
2
for BAK, p,0.0001).
Figure 1 Photographs of rabbit eyes 4 h
after the 15 instillations of phosphate-
buffered saline (A: PBS), preservative-free
tafluprost (B: PF tafluprost), latanoprost
(C) or 0.02% benzalkonium chloride (D:
BAK). (E) Draize test scores at H4 and D1
after treatment instillation. *p,0.005
compared with PBS; #p,0.01 compared
with PF-tafluprost; 1p,0.05 compared
with latanoprost.
Laboratory science
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We observed a slight inflammatory infiltration and disorganisa-
tion only after instillations of BAK (fig 2.3D).
No abnormalities of the posterior stroma or endothelium
were observed with any treatment (data not shown).
Limbus
No obvious responses were seen in the PBS and PF-tafluprost
groups (fig 2.4A,B). In the latanoprost (fig 2.4C) and BAK
(fig 2.4D) groups, we observed obvious inflammatory infiltra-
tions in the peripheral cornea and the limbus area.
Figure 2 In vivo confocal images of
rabbit corneal superficial epithelium (line
1), basal epithelium (line 2), anterior
stroma (line 3), limbus (line 4) and
conjunctival stroma (line 5) after
instillations of: phosphate-buffered saline
(A: PBS), preservative-free tafluprost (B:
PF-tafluprost), latanoprost (C) or
benzalkonium chloride (D: BAK), at D1.
The scale bar indicates 100 mm. (E) In
vivo confocal microscopy (IVCM) score
evaluation at H4 and D1 after treatment
instillation. *p,0.0005 compared with
PBS; #p,0.0005 compared with PF-
tafluprost; 1p,0.005 compared with
latanoprost.
Laboratory science
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Both the PBS and PF-tafluprost instilled rabbits presented
normal conjunctival blood vessels without any rolling inflam-
matory cells (fig 2.5A,B). In the latanoprost (fig 2.5C) and BAK
(fig 2.5D) groups, obvious rolling of inflammatory cells was
recorded.
The IVCM score evaluation to quantify the whole ocular
surface abnormalities showed no significant differences at H4
and D1 between PF-tafluprost and PBS (fig 2E). Latanoprost and
BAK showed higher IVCM scores compared with both PBS and
PF-tafluprost (p,0.0005 for all comparisons). Interestingly,
latanoprost induced lower IVCM scores than did BAK alone
(p,0.005) at both H4 and D1. At D4, IVCM scores remained
the highest after BAK-alone application (p,0.01 compared with
the three other groups; data not shown). However, there were
no differences in IVCM scores between latanoprost, PBS or PF-
tafluprost groups. At D7, BAK-alone treated eyes returned to
normal IVCM scores (data not shown).
Cresyl violet staining and FCM analysis on CIC
CIC specimens from rabbit eyes instilled with PBS showed a
homogeneous cell sheet (fig 3A, table 2): the epithelial cells were
flat and regular, with a nucleo:cytoplasmic ratio from 1:2 to 1:3.
Goblet cells were clearly visible among or beside the epithelial
cells. PF-tafluprost (fig 3B) instillation induced slight anisocy-
tosis in the epithelium with normal nuclei. Slight infiltration of
inflammatory cells could also be observed. The goblet cell
number and morphology remained normal. Significant inflam-
matory infiltration was observed after the instillation of
latanoprost (fig 3C) and BAK (fig 3D). In latanoprost-receiving
eyes, a few conjunctival epithelial cells could still be observed,
adjacent to inflammatory patches, with important anisocytosis
and anisonucleocytosis. In BAK-receiving eyes, patches of
inflammatory cell-containing secretions without any epithelial
cells were observed. The abundant inflammatory cell infiltrates
consisted mainly of neutrophils (polymorphonuclear cells)
(arrows), lymphocytes (arrowheads) and rare eosinophils (star)
(fig 3D1,D2). No goblet cells could be seen in these conditions.
At H4, PBS and PF-tafluprost induced 11.38 (3.68)% and 25.36
(4.98)% of CD45+ cells (fig 3E), respectively, with no difference.
Latanoprost and BAK groups induced 65.38 (12.58)% and 65.95
(11.06)%, respectively, both of which were significantly higher
than PBS and PF-tafluprost instillations (p,0.05 for all
comparisons). At D1, latanoprost- and BAK-instilled groups
still showed a higher expression (30.58 (1.49)% and 31.73
(1.27)%) than did PBS or PF-tafluprost (p,0.05 for the two
groups). At H4, TNFR1+ cells were also observed after the
instillation of BAK (fig 3F) (50.35 (6.96)%; p,0.05 compared
with all other groups) and latanoprost (12.43 (5.41)%; p,0.05
compared with BAK alone). There were no significant differ-
ences between PBS or PF-tafluprost instilled groups. At D1 after
instillation, the strong expression of TNFR1 in the BAK-alone
group decreased to 20.25 (8.87)%, but it was still significantly
higher than in PBS or PF-tafluprost (p,0.05) instilled eyes.
Immunohistology of CD45 and TUNEL positive cells in rabbit
cryosections
The immunostaining results of CD45+ and TUNEL+ cells at D1
are shown in fig 4A–D. The counts of positive cells were
presented as cells/mm
2 (fig 4E,F).
PBS and PF-tafluprost-instilled rabbit eyes showed only a few
CD45+ inflammatory cells in the limbus (fig 4.1A,B) and
conjunctiva (fig 4.2A,B) without any statistically significant
differences. Latanoprost and BAK induced numerous CD45+
inflammatory cells in limbal and conjunctival areas: in the
limbus, 1490 (132.04) cells/mm
2 were found for latanoprost
(fig 4.1C), and 1200 (115.47) cells/mm
2 for BAK (fig 4.1D), with
no differences. In the conjunctiva, 1480 (90.43) cells/mm
2 were
counted for latanoprost (fig 4.2C) and 1350 (121.34) cells/mm
2
for BAK (fig 4.2D). The numbers of CD45+ cells were similar
between latanoprost and BAK, and were significantly higher in
both groups compared with the PBS (p,0.0001) and PF-
tafluprost (p,0.0001) groups.
A similar trend was found for TUNEL+ apoptotic cells. Few
TUNEL+ apoptotic cells were observed after instillation of PBS
or PF-tafluprost instillations. For latanoprost, 630 (36.67)/mm
2
TUNEL+ apoptotic cells in the limbus (fig 4.3C) and 810
(67.41)/mm
2 in the conjunctiva (fig 4.4C) were seen (p,0.0001
compared with both PBS and tafluprost groups). Similar counts
were found for BAK instillation (p,0.0001 compared with both
PBS and tafluprost groups). These apoptotic cells were located
especially in the epithelial layers and in the anterior stroma. In
the conjunctiva, they were observed in particular abundance in
the epithelial layers and also in the stroma.
DISCUSSION
Fifteen repeated instillations of commercialised eye-drops can be
considered a pertinent and sensitive model as it can distinguish
between different levels of toxicity. Using in vivo tandem
scanning confocal microscopy, this model was able to help
distinguish between the toxicity ranking of 0.02%, 0.01% and
0.005% BAK concentrations by clearly showing the dose-
dependent levels of epithelial deterioration.
21 Without modify-
ing the concentration and/or composition of the tested drugs,
this present model of acute instillations appears useful for
future drug toxicity evaluations because it combines rapidity
and efficiency when comparing the toxicity of several products.
Nevertheless, although convenient and rapid for between-drug
comparisons, it should only be considered as an experimental
model, as it is relatively aggressive and does not reflect real
administration in patients. The clinical relevance of this
experiment is that the lack of toxicity in this acute instillation
model is a good indicator of further absence of ocular toxicity in
a more conventional use in the long-term for glaucoma patients.
PF-tafluprost tested in this in vivo study presented almost
similar results to PBS after clinical and IVCM observations, CIC
analysis and inflammatory or apoptotic immunopositive cell
counts in cryosections. Latanoprost solution and BAK alone
were much more toxic than the PF-tafluprost solution.
However, latanoprost instillations induced less toxicity than
did BAK in rabbit ocular surface, especially with the Draize test
evaluation at D1, IVCM scores at H4 and D1, and CIC analysed
by FCM for TNFR1 at H4. PF-tafluprost was better tolerated on
the rabbit ocular surface than the classic preservative-containing
PG-analogue latanoprost solution. The good tolerability of PF-
tafluprost is probably linked to the absence of preservative in
the solution, and so we would speculate that a PF-latanoprost
solution would have a similar tolerability on the ocular surface.
Indeed, the main toxic effects of antiglaucoma treatments
reported in the literature are related to the doses of preservative
commonly used in eye-drop formulations.
4–6 Topical antiglau-
coma treatments with high concentrations of BAK are known
to induce significant ocular surface changes, including tear-film
drying,
24 25 thickening of corneal epithelium, the loss of goblet
cells,
7 inflammatory cell infiltration and proliferation in the
conjunctiva,
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studies have shown low levels of inflammatory reactions
compared with those seen with beta-adrenoceptor antagonists
or multiple treatments, despite rather high concentrations of
BAK in the commercial solutions.
43 0Conversely, in toxicological
studies carried out in conjunctival cell lines, the PG molecules
seem to present a protective effect against BAK-induced
toxicity.
563 0In this present in vivo model using 15 successive
instillations in rabbit eyes, latanoprost also presented less
toxicity than 0.02% BAK alone, especially in clinical criteria
and CIC inflammatory marker expression.
The new PG analogue with a PF formulation, tafluprost, has
shown promising results in clinical and experimental studies. In
healthy males, the 0.0025% and 0.005% concentrations of
tafluprost were generally well tolerated; tafluprost at 0.005%
reduced IOP more than placebo or 0.005% latanoprost.
31 In an in
vitro study concerning immortalised epithelial cell line from
normal human conjunctiva, treatment with PF-tafluprost
resulted in a significantly higher membrane integrity, with
lower pro-apoptotic and pro-oxidative effects when compared
with commercially available solutions of latanoprost, travoprost
and bimatoprost.
15
The present toxicological study was based on a combination
of original, technical, ex vivo and in vivo tools to explore the
whole ocular surface. IVCM is well adapted to the transparent
corneal tissues. Conversely, CIC are more suitable for con-
junctival epithelium than corneal epithelium, as corneal
epithelial cells are too cohesive and are difficult to detach and
collect onto the membrane. Conjunctiva plays a role in ocular
defence, which is an important tissue with which to explore the
inflammatory aspects of deleterious effects induced by xeno-
biotics on the ocular surface.
Figure 3 Cresyl violet-stained
conjunctival impression cytology from
rabbits instilled with phosphate-buffered
saline (A: PBS), preservative-free
tafluprost (B: PF-tafluprost), latanoprost
(C) or 0.02% benzalkonium chloride (D:
0.02% BAK) (original size 640).
Conjunctival impression cytology
expressions of (E) CD45+ and (F) tumour
necrosis factor-receptor 1 (TNFR1)
evaluated by flow cytometry. *p,0.05
compared with PBS; #p,0.05 compared
with PF-tafluprost; 1p,0.05 compared
with latanoprost.
Table 2 Description of cresyl violet impression cytology at 4 h
Phosphate-
buffered saline Preservative-free tafluprost Latanoprost 0.02% benzalkonium chloride
Nucleo:cytoplasmic ratio 1:2–1:3 1:2–1:3 Cell borders not clear No epithelial cells visible
Ratio non-applicable
Anisocytosis/anisonucleocytosis – + +++ No epithelial cells visible
Cell size Normal Normal Very irregular Non-applicable
Inflammatory cells – ++ ++++ ++++
Goblet cells Normal Normal Goblet cell imprint, no more complete cell Could not been seen
Goblet cells:epithelial cells ratio, % 14 15 0 0
–, no abnormality; +, discrete; ++, moderate; +++, important; ++++, extremely intense.
Laboratory science
1280 Br J Ophthalmol 2008;92:1275–1282. doi:10.1136/bjo.2008.138768Figure 4 Immunohistology of CD45+ and TUNEL+ cells in rabbit cryosections at D1 after instillations of: phosphate-buffered saline (A: PBS),
preservative-free tafluprost (B: PF-tafluprost), latanoprost (C) or benzalkonium chloride (D: BAK). The scale bars indicate 100 mm. (E) CD45+ and (F)
TUNEL+ cell counts in limbus and conjunctiva of rabbit cryosections at D1 after eye-drop instillations. *p,0.0001 compared with PBS; #p,0.0001
compared with PF-tafluprost.
Laboratory science
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toxicity profiles of newly developed ophthalmic drugs. Our
results showed that 0.02% BAK, chosen as a positive control of
toxicity, was the most toxic agent tested. This was followed by
latanoprost, which contains the same concentration of BAK but
showed a tendency to be less toxic and confirms previous
reports.
4–6 Furthermore, we confirmed that the new antiglau-
coma PG-analogue, PF-tafluprost, was very well tolerated as
was PBS. Overall, the rabbit corneoconjunctival surface showed
a better tolerance when treated with PF-tafluprost than with
latanoprost or 0.02% BAK solution.
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